S&P Futures
4,065.75 -9.75 (-0.24%) Dow Futures
34,014.00 -9.00 (-0.03%) Nasdaq Futures
12,043.75 -63.00 (-0.52%) Russell 2000 Futures
1,907.50 -3.00 (-0.16%) Crude Oil
82.32 +1.31 (+1.62%) Gold
1,930.20 +0.20 (+0.01%)
Columbia Large Cap Index Fund Institutional 2 Class (CLXRX)
| Previous Close | 47.90 |
| YTD Return | -18.00% |
| Expense Ratio (net) | 0.20% |
| Category | Large Blend |
| Last Cap Gain | 0.00 |
| Morningstar Rating | ★★★★★ |
| Morningstar Risk Rating | Average |
| Sustainability Rating |
| Net Assets | 2.89B |
| Beta (5Y Monthly) | 1.00 |
| Yield | 1.25% |
| 5y Average Return | N/A |
| Holdings Turnover | 2.00% |
| Last Dividend | 0.11 |
| Average for Category | N/A |
| Inception Date | Nov 08, 2012 |
- Simply Wall St.
Investors in Humanigen (NASDAQ:HGEN) from a year ago are still down 89%, even after 14% gain this past week
It's nice to see the Humanigen, Inc. ( NASDAQ:HGEN ) share price up 14% in a week. But that doesn't change the fact...
- Business Wire
Humanigen Reports First Quarter 2022 Financial Results
SHORT HILLS, N.J., May 05, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called "cytokine storm" with its lead drug candidate, lenzilumab (LENZ®), today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.
- Business Wire
Humanigen Announces Participation and Presentation at Multiple Conferences in May
SHORT HILLS, N.J., May 04, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced today that management will present and participate at multiple investors conferences in May 2022. Details of the conferences are as follows:
